Literature DB >> 35477975

Exosomes derived from hypoxia-induced alveolar epithelial cells stimulate interstitial pulmonary fibrosis through a HOTAIRM1-dependent mechanism.

Lin Chen1,2, Yang Yang1,2, Ruiming Yue2,3, Xiaying Peng1,2, Hua Yu2,4, XiaoBo Huang5,6.   

Abstract

Pulmonary fibrosis is the result of various diseases with no satisfactory treatment approaches. The exosome-mediated transfer of long noncoding RNAs (lncRNAs) has been implicated in the pathological process of lung diseases. Herein, we investigated the therapeutic potential of HOTAIRM1 transferred by alveolar epithelial cell (AEC)-derived exosomes in interstitial pulmonary fibrosis (IPF) and the potential molecular mechanisms. Next-generation sequencing-based gene expression profiling was employed to identify lncRNAs related to IPF. Exosomes were isolated from hypoxia-induced AECs (AEC-exosomes) and identified before use. HOTAIRM1 expression was examined in bleomycin-induced IPF mouse models and the isolated exosomes, and the miRNA downstream of HOTAIRM1 was analyzed. HOTAIRM1 expression was increased in the lung tissues of IPF mice and AEC exosomes. HOTAIRM1 delivered by AEC-exosomes promoted the proliferation and transdifferentiation of lung fibroblasts (LFs). Mechanistically, HOTAIRM1 competitively bound to miR-30d-3p and recruited YY1 to upregulate HSF1 expression. In addition, miR-30d-3p targeted HSF1 by binding to its 3'-UTR and reduced its expression. In vivo assays confirmed the promoting effect of exosomes-HOTAIRM1 on extracellular matrix remodeling by regulating the miR-30d-3p/HSF1/YY1 axis. Overall, HOTAIRM1 loaded by AEC exosomes can accelerate IPF by disrupting miR-30d-3p-mediated inhibition of HSF1 and inducing recruitment of HSF1 by YY1. These results highlight a promising strategy to overcome IPF.
© 2022. The Author(s), under exclusive licence to United States and Canadian Academy of Pathology.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35477975     DOI: 10.1038/s41374-022-00782-y

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.502


  3 in total

Review 1.  Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis.

Authors:  Keith C Meyer
Journal:  Expert Rev Respir Med       Date:  2017-04-10       Impact factor: 3.772

Review 2.  Role of Microbial Agents in Pulmonary Fibrosis
.

Authors:  Ozioma S Chioma; Wonder P Drake
Journal:  Yale J Biol Med       Date:  2017-06-23

3.  Long Non-Coding RNA Hotairm1 Promotes S100A9 Support of MDSC Expansion during Sepsis.

Authors:  Tuqa Alkhateeb; Isatou Bah; Ajinkya Kumbhare; Dima Youssef; Zhi Q Yao; Charles E McCall; Mohamed El Gazzar
Journal:  J Clin Cell Immunol       Date:  2020-09-22
  3 in total
  4 in total

1.  Long Non-Coding RNAs in Cardiac and Pulmonary Fibroblasts and Fibrosis.

Authors:  Mirolyuba Ilieva; Shizuka Uchida
Journal:  Noncoding RNA       Date:  2022-07-15

Review 2.  Exosomes in pathogenesis, diagnosis, and treatment of pulmonary fibrosis.

Authors:  Yang Yang; Yufei Liu; Yilu Chai; Ke Liu; Wei Hu; Keni Zhao; Yi Zhu; Peiyang Gao; Qingsong Huang; Chuantao Zhang
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

Review 3.  Roles of exosomes and exosome-derived miRNAs in pulmonary fibrosis.

Authors:  Yongfeng Yang; Hong Huang; Yi Li
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

Review 4.  Exosomal Micro-RNAs as Intercellular Communicators in Idiopathic Pulmonary Fibrosis.

Authors:  María Cristina Negrete-García; Javier de Jesús Ramos-Abundis; Noé Alvarado-Vasquez; Eduardo Montes-Martínez; Martha Montaño; Carlos Ramos; Bettina Sommer
Journal:  Int J Mol Sci       Date:  2022-09-20       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.